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Alcoholic liver disease (ALD) is characterized by the spectrum of liver injury ranging from 
steatosis, inflammation, fibrosis, and eventually cirrhosis1. The pathogenesis of ALD is 
complex involving many specific intracellular signaling pathways, transcription factors, 
innate immunity, and epigenetic alterations (reviewed by Gao et al1). The effect on these 
pathways could be directly from alcohol or indirectly from acetaldehyde, its metabolite, via 
alcohol dehydrogenase (ADH) and CYP2E11. The transcription factor, sterol regulatory 
element-binding protein 1c (SREBP-1c), regulates lipogenic genes to control intrahepatic 
fatty acid synthesis2. Alcohol consumption increases SREBP-1c transcription via its 
metabolite acetaldehyde or down-regulates its suppressors, such as Sirtuin1 (SIRT1)3, 4.
In addition to SREBP-1c, carbohydrate-responsive element-binding protein (ChREBP) is 
another transcription factor with a key role in glucose and lipid metabolism. ChREBP 
contains two nuclear export signals and one nuclear localization signal near the N-terminal, 
proline-rich domains, a basic helix-loop-helix leucine-zipper (b/HLH/Zip), and a leucine-
zipper-like domain5. Transcriptional targets of ChREBP include L-pyruvate kinase (L-PK) 
and fatty acid synthase (FAS) which are important enzymes for the regulation of glucose 
and lipid metabolism respectively5. Activity of ChREBP can be regulated through post-
translational modifications (as shown in Table 1). The importance of ChREBP in the 
pathophysiology of hepatic steatosis in non-alcoholic fatty liver disease has been described5; 
however, its role in the pathogenesis of ALD is not yet clear.
In this issue of HEPATOLOGY, Marmier et al. report a novel finding of the ChREBP/
SIRT1/ADH axis in the control of alcohol metabolism and pathobiology of alcohol-induced 
hepatic steatosis in mice using a ‘binge drinking’ model6. In contrast to chronic alcohol 
drinking, which induces ChREBP activity through dephosphorylation7, binge drinking 
induces ChREBP through acetylation6. Acetylated ChREBP binds to the SIRT1 promoter 
and suppresses its transcription; this represents a unique mechanism by which alcohol can 
inhibit SIRT1. The involvement of ChREBP in alcohol-induced hepatic steatosis was 
confirmed by Marmier et al. with ‘loss of function’ experiments, wherein silencing ChREBP 
prevents intrahepatic triglyceride accumulation. They also found that acetaldehyde is the 
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precursor for acetate and acetyl-CoA, the source of the acetyl group incorporated on 
ChREBP6. When alcohol-mediated induction of ADH activity is blocked by 4-
methylpyrazole, ChREBP acetylation and the expression of its downstream lipogenic genes 
are reduced.
While the findings of Marmier et al. suggest that CHREBP might be an attractive 
therapeutic target for ALD, the authors observed a high mortality rate in mice lacking 
ChREBP during multiple gavages of alcohol due to hypothermia and hypoglycemia. These 
mice had high blood alcohol levels, but reduced hepatic concentrations of alcohol 
metabolites, acetaldehyde, acetate and acetyl-CoA, suggesting that alcohol metabolism was 
inhibited in ChREBP-silenced mice. To further elucidate the mechanism, the authors found 
that ADH can be regulated by SIRT1 through deacetylation6. Silencing ChREBP decreased 
ADH acetylation and its enzymatic activity through the activation of SIRT16. Their 
discovery helps to explain the phenotype of alcohol intoxication in ChREBP-silenced mice 
following binge alcohol drinking.
A few observations from this study deserve further discussion. First, the blood alcohol 
kinetics after alcohol gavage are different from a previous report8. After gavage (at a dose of 
alcohol ~3–6 g/kg), alcohol is rapidly absorbed and blood alcohol concentration (BAC) 
peaks within 1–2 hr(s) and reduces to almost undetectable levels by 8–10 hrs8. Marmier et 
al. observed the peak of BAC at ~8–10 hrs, a peculiarly delayed BAC kinetics, with no clear 
explanation. Second, alcohol intoxication, especially in an undernourished or fasting person, 
can cause hypoglycemia; presumably from the inhibitory effects of alcohol on hepatic 
gluconeogenesis, when hepatic glycogen is depleted9. In such a situation, the liver simply 
cannot handle the reducing equivalents (NADH+) provided by alcohol metabolism, through 
ADH, fast enough to prevent metabolic derangements. The excess in NADH+ blocks the 
conversion of lactate to glucose, leading to hypoglycemia9. Paradoxically, Marmier et al. 
instead found profound hypoglycemia in mice lacking ChREBP6, while ADH was 
inactivated; thus reducing alcohol metabolism and lowering the level of NADH+. Previous 
metabolite and enzyme activity analyses revealed that the hepatic pyruvate level, the 
substrate for gluconeogenesis, in ChREBP-silenced mice is significantly lower compared to 
the wild-type counterparts because of the decreased hepatic glycolysis in response to an 80% 
reduction in L-PK activity10. The status of hepatic pyruvate and glycogen, which were not 
examined, may therefore contribute to the hypoglycemia in this study.
Previous studies have shown that ADH genes are primarily regulated through transcription 
factors (such as C/EBPα, HNF-1) binding to the proximal promoters at cis-acting 
elements11. Marmier et al. are first to demonstrate that ADH can be regulated through 
deacetylation by SIRT16. The finding provides additional mechanistic insight into the role 
of SIRT1 on alcohol metabolism and in the pathogenesis of ALD. It also provides us a new 
perspective when considering SIRT1 as a therapeutic target for ALD. You et al. have shown 
that chronic alcohol exposure inhibits SIRT1, through miR-217/lipin 1, which leads to an 
increase in the acetylated form of SREBP-1c and activation of lipogenic genes3, 4, 12. 
Decreasing SIRT1 may also activate ADH through acetylation and increase the levels of 
acetylated ChREBP6. This, by itself, could directly activate lipogenesis or further inhibit 
SIRT1, leading to a vicious cycle which eventually aggravates the progression of ALD 
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(Figure 1). The connection among SIRT1, ADH acetylation associated with its kinetics/
activity, and alcohol metabolism should therefore be further dissected in SIRT1 knockout 
mice treated with alcohol.
Activating SIRT1 can de-acetylate ADH and increase the risk of alcohol intoxication 
through the inhibition of alcohol metabolism6. This is the ‘yin and yang’ dilemma of using 
SIRT1 activators, such as resveratrol, in ALD treatment, as it may have differential effects 
depending on the patterns of alcohol consumption. In chronic drinkers, resveratrol might 
provide the benefit in the reduction of hepatic steatosis, as previously shown in mice 
chronically fed alcohol for 4 weeks12. In this scenario, BAC is likely not exceedingly high, 
and alcohol can still be metabolized due to the low Km of ADH enzymes for alcohol 
(particularly in Caucasian populations)13, even when ADH activity is partially inhibited by 
resveratrol. However, in those with chronic plus binge drinking, resveratrol might lead to 
alcohol intoxication, because the reduction in ADH activity may be insufficient to 
metabolize a surge in blood alcohol levels during a binge episode. Clearly, future 
experiments are needed to test these assumptions. Lastly, this study raises some concerns in 
targeting acetaldehyde for the treatment of ALD. While previous report suggests that 
increased acetaldehyde clearance by activation of its catalytic enzyme aldehyde 
dehydrogenase2 (ALDH2) attenuates hepatic steatosis14, paradoxical increase in hepatic 
lipogenesis may be observed, particularly in binge drinkers, if acetaldehyde metabolites feed 
forward to activate ChREBP (Fig 1).
In summary, Marmier et al6 described the novel role of the ChREBP/SIRT1/ADH pathway 
in the control of alcohol and lipid metabolism. However, further detailed studies are needed 
to identify the location of the acetylated lysine residues on ADH and to confirm whether 
ADH activity is regulated by acetylation. Finally, the effect of SIRT1 activator on ADH 
activity, alcohol pharmacokinetics, ChREBP, and hepatic lipogenesis in vivo using different 
alcohol feeding models should be carefully determined. This may provide profound insights 
into the roles of this intricate pathway in the pathogenesis of ALD.
List of Abbreviations
ALD alcoholic liver disease
ADH alcohol dehydrogenase
ALDH aldehyde dehydrogenase
BAC blood alcohol concentration
C/EBP CCAAT-enhancer-binding proteins
ChREBP Carbohydrate-responsive element-binding protein
CYP2E1 cytochrome P450 2E1 enzyme
FAS fatty acid synthase
HAT histone acetyl-transferase
HNF1 hepatocyte nuclear factor1
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SREBP-1c sterol regulatory element-binding protein 1c
SIRT1 silent mating type information regulation 2 homolog 1
Reference List
1. Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. 
Gastroenterology. 2011; 141(5):1572–1585. [PubMed: 21920463] 
2. You M, Fischer M, Deeg MA, Crabb DW. Ethanol induces fatty acid synthesis pathways by 
activation of sterol regulatory element-binding protein (SREBP). J Biol Chem. 2002; 277(32):
29342–29347. [PubMed: 12036955] 
3. Yin H, Hu M, Zhang R, Shen Z, Flatow L, You M. MicroRNA-217 promotes ethanol-induced fat 
accumulation in hepatocytes by down-regulating SIRT1. J Biol Chem. 2012; 287(13):9817–9826. 
[PubMed: 22308024] 
4. Yin H, Hu M, Liang X, et al. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling 
and aggravates alcoholic fatty liver. Gastroenterology. 2014; 146(3):801–811. [PubMed: 24262277] 
5. Xu X, So JS, Park JG, Lee AH. Transcriptional control of hepatic lipid metabolism by SREBP and 
ChREBP. Semin Liver Dis. 2013; 33(4):301–311. [PubMed: 24222088] 
6. Marmier S, Dentin R, Daujat-Chavanieu M, et al. Novel role for ChREBP in the control of ethanol 
metabolism and susceptibility to binge drinking. Hepatology. 2015
7. Liangpunsakul S, Ross RA, Crabb DW. Activation of carbohydrate response element-binding 
protein by ethanol. J Investig Med. 2013; 61(2):270–277.
8. Carson EJ, Pruett SB. Development and characterization of a binge drinking model in mice for 
evaluation of the immunological effects of ethanol. Alcohol Clin Exp Res. 1996; 20(1):132–138. 
[PubMed: 8651442] 
9. Harris, RA. Carbohydrate metabolism. In: Devlin, T., editor. Textbook of Biochemistry with 
Clinical Correlations. 6th. 2006. p. 581-635.
10. Burgess SC, Iizuka K, Jeoung NH, et al. Carbohydrate-response element-binding protein deletion 
alters substrate utilization producing an energy-deficient liver. J Biol Chem. 2008; 283(3):1670–
1678. [PubMed: 18042547] 
11. Edenberg HJ. Regulation of the mammalian alcohol dehydrogenase genes. Prog Nucleic Acid Res 
Mol Biol. 2000; 64:295–341. [PubMed: 10697413] 
12. Ajmo JM, Liang X, Rogers CQ, Pennock B, You M. Resveratrol alleviates alcoholic fatty liver in 
mice. Am J Physiol Gastrointest Liver Physiol. 2008; 295(4):G833–G842. [PubMed: 18755807] 
13. Crabb DW, Matsumoto M, Chang D, You M. Overview of the role of alcohol dehydrogenase and 
aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr 
Soc. 2004; 63(1):49–63. [PubMed: 15099407] 
14. Zhong W, Zhang W, Li Q, et al. Pharmacological activation of aldehyde dehydrogenase 2 by 
Alda-1 reverses alcohol-induced hepatic steatosis and cell death in mice. J Hepatol. 2014
15. Kabashima T, Kawaguchi T, Wadzinski BE, Uyeda K. Xylulose 5-phosphate mediates glucose-
induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc Natl 
Acad Sci U S A. 2003; 100(9):5107–5112. [PubMed: 12684532] 
16. Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links 
transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic 
steatosis in mice. J Clin Invest. 2010; 120(12):4316–4331. [PubMed: 21084751] 
17. Guinez C, Filhoulaud G, Rayah-Benhamed F, et al. O-GlcNAcylation increases ChREBP protein 
content and transcriptional activity in the liver. Diabetes. 2011; 60(5):1399–1413. [PubMed: 
21471514] 
Liangpunsakul Page 4









Fig 1. Complex mechanisms and the interplay of ChREBP, SIRT1, and ADH in the regulation of 
alcohol and lipid metabolism in hepatocytes
The regulation of SIRT1 and ChREBP by alcohol depends on the drinking pattern. Chronic 
alcohol drinking inhibits SIRT1, through miR-217/lipin 1, which leads to an increase in the 
acetylated form of SREBP-1c and activation of lipogenic genes3, 4, 12. In contrast to chronic 
alcohol drinking, which induces ChREBP activity through dephosphorylation7, binge 
drinking induces ChREBP through acetylation6. Acetylated-ChREBP (ChREBPAC) binds to 
the SIRT1 promoter and inhibits its activity. A decrease in SIRT1 activity is proposed to 
activate ADH activity through increased acetylation. This results in the acceleration of 
alcohol metabolism, increasing intrahepatic acetaldehyde, and ChREBPAC. ChREBPAC can 
directly activate lipogenic genes or further inhibit SIRT1, leading to a vicious cycles which 
eventually aggravate the progression of ALD in binge drinkers. Activating SIRT1 with 
compound such as resveratrol can de-acetylate ADH and increase the risk of alcohol 
intoxication through the inhibition of alcohol metabolism, as shown in red6. This leads to the 
therapeutic dilemma of using SIRT1 activators as the therapeutic potential for the treatment 
of ALD, especially in binge drinkers.
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Post-translational modifications regulating the activity of ChREBP
Enzyme Mechanism Activity Outcomes
cAMP-dependent protein kinase 
(protein kinase A)15
Phosphorylation at Ser-196 and Thr-666 
of ChREBP protein
Decrease Inactivation of nuclear translocation and 
DNA binding activity
Protein phosphatase 2A15 Dephosphorylation at Ser-196 and 
Thr-666 of ChREBP protein
Increase Activation of nuclear translocation and 
DNA binding activity of its target genes
histone acetyltransfer-ase (HAT) 
coactivator p30016
Acetylation of ChREBP at Lys672 Increase Enhancing the recruitment of ChREBP to 
its target gene promoters
O-GlcNAc transferase17 O-GlcNAcylation at serine/threonine 
residues of ChREBP protein
Increase Stabilizing the ChREBP protein and 
increasing its transcriptional activity
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